Very little data exist regarding the effect of cardiopulmonary bypass (CPB) on cefuroxime (CXM) pharmacokinetics in children less than one year of age.
METHODS

mg kg
À1 CXM i.v. after induction were followed by 75 mg kg À1 into the CPB circuit. In 42 patients undergoing cardiac surgery, 15-20 samples were obtained between 5 and 360 min after the first dose. Total CXM concentrations were measured by highperformance liquid chromatography and a pharmacokinetic/pharmacodynamic (PK/PD) modelling was performed.
RESULTS
Using a fixed protein binding of 15.6% for CXM, peak plasma concentrations of unbound CXM were 229 ± 52 μg ml À1 after the first bolus and 341 ± 86 μg ml À1 on CPB. Nadir concentrations before CPB were 69 ± 20 μg ml À1 and six hours later decreased to 41 ± 19 μg ml À1 with and 24 ± 14 μg ml À1 without CPB. A two-compartment model was fitted with the main covariates body weight, CPB and postmenstrual age (PMA). PK parameters were as follows: systemic clearance, 5.15 [95% CI 4.5-5.8] l h À1 ; central volume of distribution, 11.25 [9.41-13 .09] l; intercompartmental clearance, 18.19 [14.79-21 .58] l h À1 ; and peripheral volume, 17.07 [15.7-18 .5] L. ƒT > MIC of 32 μg ml À1 for an 8-h time period was between 70 and 100% (2.5-10 kg BW). According to our simulation, 25 mg ml À1 CXM as a primary bolus and into the prime plus a 5 mg kg À1 h À1 infusion maintain CXM concentrations continuously above 32 μg ml À1 .
CONCLUSIONS WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Perioperative antibiotic prophylaxis is routinely used during cardiac surgery to reduce wound, surgical site and bloodstream infections.
• While cefuroxime pharmacokinetics during adult cardiac surgery have been studied widely, dosing strategies in paediatric cardiac surgery are mostly adapted from adult dosing or based on empirically derived schedules.
• Until now, no pharmacokinetic data in children younger than 1 year old exist.
WHAT THIS STUDY ADDS
• We report the total plasma concentrations of cefuroxime in this patient population of children undergoing cardiac surgery with CPB and mild hypothermia.
• The data fitted a two-compartment model and the main covariates were allometrically-scaled bodyweight, CPB and PMA, which mostly affected clearance terms.
• Dosing simulation supported a CXM regimen of 25 mg kg À1 as a primary bolus and into the CPB prime and a 5 mg kg À1 h
À1
infusion throughout the perioperative course to maintain CXM concentrations above 32 mg l À1 .
Introduction
Surgical site infections (SSI) after paediatric cardiac surgery occur at a rate of 3.4% despite standard antibiotic prophylaxis, with an additional risk of 5.3% for blood stream infections (BSI) adding up to a total risk of 8.7% for infectious complications [1] . Age less than one year, excessive blood loss and incorrect timing of antibiotic prophylaxis were consistently identified as risk factors [1] [2] [3] . Usually, a first-or second-generation cephalosporine like cefazolin or cefuroxime (CXM) is infused within 1 h before surgical incision. While both are interchangeable for prophylaxis, cefuroxime provides better Gram-negative coverage. Most Gram-positive and Gram-negative bacteria are sufficiently inhibited by cefuroxime in concentrations four times above the minimum inhibitory concentrations (MIC) [4] . For Gram-positive bacteria, 16 μg ml À1 has been considered appropriate referring to a MIC between 1 and 4 μg ml À1 . To gain appropriate Gram-negative coverage, MIC values of unbound cefuroxime need to be increased up to 32 μg ml À1 (MIC ≥ 8 μg ml À1 ) according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines [5, 6] . The plasma elimination of cefuroxime is characterized by a halflife of 1-2 h [7] but limited data are available for the intraoperative pharmacokinetics in children less than one year of age undergoing cardiopulmonary bypass [8] . Even the latest guidelines exclude this particular age group in their recommendations [2] . β-Lactam antibiotics exhibit a time-dependent bactericidal action with minimal post-antibiotic effects [4] . Therefore, exceeding a threshold value for a sufficient period of time approximated by the MIC of the causative pathogen, which is equivalent to the minimal serum concentration of the free drug, is the single most important parameter for predicting the efficacy [9] . Minimal bactericidal effect for cefuroxime was estimated to be at a fraction of time fT > MIC of 41% [10] and maximal bactericidal activity is reached for fT > MIC approaching 60-70% [11] . However, one could argue that even an fT > MIC of 100% should be targeted perioperatively. Since bacterial contamination occurs any time, the goal of antimicrobial prophylaxis should be to achieve serum and tissue drug concentrations that exceed pathogen MICs for the entire duration of the operation. A recent paediatric study observed that 95% of critically ill children did not achieve target concentrations with current dosing recommendations [12] . Our investigation started off as a quality improvement measure to explore the pharmacokinetics of two different medications, namely tranexamic acid and cefuroxime. The first part examined the PK parameters of tranexamic acid [13] and the second investigation herein presents data on the pharmacokinetic course of cefuroxime in children less than one year of age. In these patients, the ratio of the priming volume of CPB to the absolute volume of distribution is greater and a more pronounced haemodilution is seen. Since both drugs share a similar halflife (t 1/2 ) of approx. 90 min, we used the same samples to reduce the number of blood withdrawals. A Monte Carlo simulation based on known clinical breakpoints [4] was performed to examine the effect of dose and frequency of cefuroxime on achieving a probability of target attainment (PTA) of fT > MIC of 100% for an 8-h period. Our goal was to provide a better understanding of the PK of this population during CPB procedures and to give a dosing proposal to achieve optimal antibiotic prophylaxis.
Methods
Clinical protocol
The study was approved by the ethics committee of the Medical Faculty of the Technical University Munich (ref. 5600/12) and registered with the WHO ICTRP/German Clinical Trials Register No. DRKS-4538. Written parental consent was obtained in all cases. Patients were children less than one year of age with a congenital heart defect undergoing cardiac surgery with (n = 36) or without (n = 6) CPB between January and June 2013. Further details on anaesthetic and bypass management can be found elsewhere [13] . Exclusion criteria were a known allergy to cefuroxime, any pre-existing antibiotic therapy with cefuroxime and renal or hepatic insufficiency. After the induction of anaesthesia and arterial line placement, a 50 mg kg À1 CXM bolus was given over 5 min and, if CPB was used, another 75 mg kg À1 was added to the prime volume. The CPB priming consisted of Ringer's acetate, 5000 IU of heparin, 100-150 ml washed packed red blood cell, 100-150 ml FFP and sodium bicarbonate. Prime volumes were approximately 370-380 ml. A non-coated bypass circuit and either a Dideco D100 oxygenator for neonates <5 kg (Sorin Group, Milano, Italy) or a Terumo Baby RX oxygenator (Terumo, Ann Arbor, MI, USA) was used. Mild hypothermia at 32-34°C was applied to all patients on CPB. After discontinuation of CPB, routine modified ultrafiltration (MUF) was used.
Population pharmacokinetic modelling
Pharmacokinetic data were analysed using the nonlinear mixed effect modelling software Phoenix 64 NLME 8.0 (Certara Inc., Princeton, NJ, USA). All models were run with the first order conditional estimation with interaction (FOCE-I) method. The parameters are elimination and intercompartmental clearances, CL and Q, and the volume of central and peripheral compartments, V1 and V2. A twocompartment open model was first fitted. The effect of CPB was modelled as a binary covariate. At first, a basic model without covariates was considered. Additive, proportional and combined residual error models were considered during the model-building process.
The following covariate effects were tested based on previous cefuroxime pharmacokinetic models and physiological and developmental principles during the first year of life: weight, postmenstrual age (PMA), renal function, CPB prime volumes, CPB as a categorical variable (on/off), temperature and MUF volumes. All covariates were centred to the adult values and their effect was estimated as θ cov . Body weight was included a priori using an allometric approach. Individual values of pharmacokinetic parameters (P i ) were described for body weight as follows:
where i denotes the ith individual and tvP the typical value of the population. The power exponents θ were tested with and without fixation at 0.75 for the clearance and 1 for the volume parameters (allometric scaling) [14] . θ CPB was introduced as modifying factor and estimated by Phoenix during the period of CPB:
for the effect of CPB as a categorical variable;
where P i denotes a clearance or volume term for the ith individual, tvP is the typical parameter value, CPB a binary variable (θ CPB = 1 when on CPB, θ CPB = 0 otherwise), with θ CPB as the influential parameters. For the impact of age on clearance, a sigmoidal maturation function based on postmenstrual age Fmat was chosen with
Hill with PMA being post-menstrual age in years, θHill as the Hill coefficient and the PMA 50 for maturation half-life [14] . PMA 50 was fixed at 0.65. Alternatively, creatinine clearance was used to estimate glomerular filtration rate (GFR) using the Schwartz formula with a proportionality constant of 0.45 for term infants less than 1 year of age [15] . CrCL was normalized and entered into the model as θ CrCL .
Model validation and selection. The Bayesian Information Criterion (BIC) was used to test different hypotheses regarding the final model. In addition, a reduction in BSV, precision parameters and goodness-of-fit plots were used to select the final covariates. From the final model, 1000 simulations were performed to generate a visual predictive check (VPC). The goodness-of-fit plots were examined with particular emphasis on the observed vs. the populationpredicted concentrations for the best predictive model. Results were visualized as a scatterplot for Pop CWRES vs. individual predicted concentrations (IPRED) or time after dose (TAD) and a prediction-corrected visual predictive check (pcVPC) stratified for weight (n = 1000 simulations). A non-parametric bootstrap analysis (n = 1000 samples) was used to assess parameter precision.
Pharmacodynamic simulations of CXM. A MIC for cefuroxime of 8 μg ml À1 was used [5, 16] . According to standard clinical antibiotic dosing goals, a minimum unbound cefuroxime concentration of 4 times the MIC (32 μg ml À1 ) was chosen as a target concentration for drug efficacy [7] . We corrected the observed CXM concentrations for protein binding at a fixed rate of 15.6% [17] . Full equilibration with the peripheral target compartment [18, 19] and unopposed access to its interstitial target sites was assumed [20] . Using a Monte Carlo simulation (n = 1000), the overall probability of achieving the PD target, referred to as the probability of target attainment (PTA), was calculated over the range of MICs between 4 and 32 mg l À1 for children between 2.5 and 10 kg BW and set at 100% for optimal dosing during the critical perioperative time period (fT > MIC of 100% for 8 h). Standard dosing, every 2 and every 4 h and a combined bolus and continuous infusion schedule were simulated. Initial doses were administered over 5 min, followed by a 90-min interval until initiation of CPB and a duration on CPB of 90 min.
Nomenclature of ligands
Key ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHAR-MACOLOGY [21] , or the PubChem database https:// pubchem.ncbi.nlm.nih.gov.
Results
Population characteristics and CXM concentrations
The patient characteristics are listed in Table S1 . There were three patients with a BSI (7.1%). On postoperative day 2, two infants required reintubation for a pneumonia with E. coli and P. aeruginosa. Another infant died 7 days after surgery from a fulminant Pseudomonas sepsis. No surgical site infections were noted.
A total of 620 samples were obtained with three outliers excluded and no sample below the lower limit of quantification (LLOQ). Individual pharmacokinetic time courses of CXM, including the predicted concentrations, are shown in Figure S1 A-E.
Peak total plasma concentrations of CXM were 271 ± 62 μg ml À1 (corresponding to 229 ± 52 μg ml À1 of free CXM) 5 min after the first bolus, and CXM concentration fell to 82 ± 24 μg ml À1 (equal to a free CXM concentration of 69 ± 20 μg ml À1 ) right before CPB. The second dose on CPB achieved peak levels of 404 ± 102 μg ml À1 (341 ± 86 μg ml
À1
of free CXM) on CPB. Six hours after the start of CPB, concentrations were at 48 ± 22 μg ml À1 (free CXM 41 ± 19 μg ml À1 , respectively). The six patients without CPB had residual total and unbound CXM concentrations of 28 ± 16 μg ml À1 and 24 ± 14 μg ml À1 6 h after their initial dose. MIC <32 mg l À1 may occur in 14% of one-year old children and up to 43% in newborn.
Population pharmacokinetic modelling
The final model building steps are summarized in Table S2 . The final covariates of the two-compartment model were allometrically scaled bodyweight using theory-based exponents of 0.75 on (CL, Q) and 1 on (V1, V2), the effect of CPB on CL and Q and PMA on CL. Table 1 shows the final population pharmacokinetic estimates and the results of the bootstrap analysis. All parameters were well estimated with low relative standard errors and an ε-shrinkage less than 10%. MUF, prime volume or temperature were devoid of effect (results not shown). The goodness-of-fit plots are depicted in Figures S2 A-E representing a good model fit. Figure S3 illustrates the visual predictive performance of the final model. Table 2 represents the PTA according to weight groups. In Figure 1A , our standard dosing schedule is shown. Figures 1B  and 1C show the guideline-recommended 4 h dosing interval and an accelerated dosing scheme with dosing repetition every 2 h. Taken together, a bolus plus infusion scheme can be best applied as shown in Figure 1D . For children less than 10 kg BW, a loading dose of 25 mg kg À1 followed by a continuous infusion of 5 mg kg À1 h À1 throughout surgery with an additional 25 mg kg À1 bolus into the prime fluid maintains free plasma CXM concentrations greater than 32 μg ml À1 .
Simulation of free CXM concentrations
Discussion
Intraoperative antibiotic prophylaxis is used to reduce wound, surgical site and bloodstream infections. While cefuroxime pharmacokinetics during adult cardiac surgery have been studied widely [7, 16, 18, [22] [23] [24] , dosing strategies in paediatric cardiac surgery are mostly adapted from those adult dosing or based on empirically derived schedules, and there was to date no pharmacokinetic data in children younger than 1 year old. We report on the plasma concentrations of cefuroxime in this patient population of children undergoing cardiac surgery with CPB and mild hypothermia. The data fitted a twocompartment model and the main covariates were allometrically-scaled bodyweight, CPB and PMA, which These PK parameters are in agreement with previously published findings in the same cohort with tranexamic acid [13] . With respect to cefuroxime in paediatrics, the only data published were obtained in older children and results were comparable to those of the present study (according to values presented in the abstract, which are much more physiologically relevant than those in the manuscript's main body) [8] . In line with our findings, an increase by about twofold in the systemic clearance was already observed with other Table 2 Fractional target attainment for various intermittent and continuous cefuroxime doses for patients with total body weights of 2.5, 5, 7.5 and 10 kg, and a duration of surgery of 8 h for minimal inhibitory concentration (MIC) distributions between 8 and 32 mg l À1 . The percentage achieving a probability of target attainment (PTA) of ƒT > MIC <100% is shown. drugs in neonates undergoing cardiac surgery [25] . By the same token, we found no effect of CPB on the distribution volumes, again in agreement with previous findings [7, 8, 16, 26] . All structural model parameters and between-subject variabilities were estimated with adequate precision (relative standard error < 15%) which was further confirmed with the bootstrap analysis. The 5th, 50th and 95th percentiles of the predicted concentrations in the pcVPC plots closely follow the percentiles of the observed data, suggesting a good model fit. With respect to the antibiotic activity, optimized dosing regimen should be aimed at reducing the rates of infection, even more in this patient group which has a higher risk of infection than adults due to their innate immunity and postoperative immunoparalysis [27] . Therefore, as recommended by the European Medicines Agency [28] , we used modelling and simulation for dose selection and proposed different intermittent or a continuous dosing regimen ('25-25-5 protocol').
The question of the duration and the magnitude of perioperative antibiotic prophylaxis remains debated [29] and there is presently no dosing strategy that ensures adequate exposure considering the influence of CPB. Infectious complications following cardiac surgery are higher in infants less than 1 year of age [30] . In our study, no case of sternal wound infection was observed, but there was a 7.1% rate of BSI with Gram-negative bacteria within the first week after surgery. Because β-lactam antibiotics exhibit time-dependent killing and no post-antibiotic effects (PAE) on Gram-negative bacilli [11, 31] , the goal for a highly effective dosing regimen would be to provide levels above the MIC for 40-50% of the dosing interval to prevent infections with S. aureus, or for 60-70% of the dosing interval for most other pathogens. The latter target was retained as an objective knowing that a significant proportion of infections are caused by Gram-negative pathogens in this paediatric cardiac surgical population [32] . However, there is no universal agreement on the fT > MIC, and an fT > MIC of up to 100% may be justified during the intraoperative phase [2] . As shown in Figure S3A , our current institutional dosing regimen (as advocated by others before [29, 33] ) did not allow us to maintain an antibiotic concentration above the therapeutic target in all patients. Our results also show that with such a regimen, a MIC <32 may occur in 14% of 1-year-old children and up to 43% in newborns. Continuous infusions allow better fine tuning of the blood concentration and require less interventions than intermittent dosing. In addition, it allows control of the fT > MIC, which is an essential endpoint with time-dependent antibiotics. With respect to the target concentration, a recent metanalysis found no significant advantage of high antibiotic dosing during cardiac surgery for adults, but increasing the prophylaxis up to 48 h post-surgery may be an advantage, easier to manage with our continuous infusion scheme than with intermittent dosing [34] .
Additional advantages of continuous infusion are numerous. First, a continuous infusion group was more efficacious than a bolus schedule and provided better tissue penetration [35, 36] . The incidence of SSI was reduced from 2.3% to 0.5% following introduction of a continuous antibiotic protocol [37] . Also, bolus application linked to procedural time points like the initiation of CPB or during wound closure might produce subtherapeutic concentrations, particularly during prolonged procedures: a CPB duration of >2 h may predispose almost 50% of patients to inadequate concentrations, stressing the importance of higher or more frequent intraoperative dosing [33] . With our current scheme, the total daily dose for prophylaxis is 125 mg kg À1 . Our optimized infusion scheme should improve the safety profile since the daily dose would be 90 mg kg À1 for an 8 h surgery, with a greater stability of drug concentration over time and a reduced peak concentration. In addition, the continuous administration of β-lactam antibiotics was not identified as an increased risk factor for renal dysfunction or seizures in an adult study comparing every 2 h dosing to a continuous protocol [38] . Our study has some limitations. First, our results should not be extrapolated to older children. Additionally, all children underwent zero balance and MUF for 10-15 min, which may impact the pharmacokinetics, but there was no significant change in the observed cefuroxime concentration at the end of CPB. Also, moderate and deep hypothermia may have an effect on renal elimination [39] . Our study included only patients undergoing CPB with mild hypothermia (between 32 and 36°C); thus our results should not be extrapolated to procedures with deeper hypothermia. Finally, the concept of using MIC over time as an indicator of antibiotic efficacy may be discussed since the dynamics of postantibiotic effects, post-antibiotic sub-MIC effects and the post-antibiotic leucocyte enhancement have to be taken into account [40] .
Even though this may be an oversimplification, the cefuroxime protein binding rate was assumed to be concentration independent [17] . This may be disturbed in the setting of cardiopulmonary bypass, where the addition of blood products to the prime may represent an additional substrate for protein-binding and changes in temperature and pH occur over a wide range [41] .
To examine the potential effects of changes in total protein/albumin content during the intraoperative period on the concentration of unbound cefuroxime in our population, we exemplarily quantified the total protein content in 48 plasma samples from four patients with CEC and five patients without CEC (Pierce ™ BCA Protein Assay KIT; Thermo Scientific, IL, USA). Assuming a constant fraction of 60% albumin of the total protein, we measured a mean albumin concentration of 43.5 ± 10.1 g l À1 before CPB. The albumin level dropped to 35.8 ± 9.2 g l À1 (À7.7%) on CPB, without significant effect of CPB.
Employing equation (4) from Benson et al. [17] and the two mean albumin concentrations before and during CPB (43.5 g l À1 and 35.8 g l À1 ), ranges in unbound cefuroxime at a peak total concentration level of total cefuroxime of 404 μg ml À1 were between 340.5 μg ml À1 and 350.3 μg ml À1 .
At our lowest total cefuroxime concentration (48 μg ml À1 ), the unbound fraction will vary between 40.5 μg ml À1 and 41.6 μg ml À1 , depending on albumin concentrations. It seems like mostly the highly-protein bound β-lactams could be affected by changes as seen for ceftriaxone and flucloxacillin, and the correction for protein binding can be considered appropriate for moderately protein-bound antibiotics like cefuroxime [42] . Our total protein measurements and calculations identified a negligible effect of about 2.2% of perioperative albumin concentrations on
Pharmacokinetics of cefuroxime in infants on CPB unbound cefuroxime levels, comparable to Aalbers et al. [22] who found a fluctuation of CXM protein binding less than 2% during adult cardiac surgery. Even the variation of the highly protein-bound antibiotic cefazolin with a subsequently higher susceptibility to changes in plasma proteins was minimal (28% ± 3%) in a group of children similar to ours using a reconstituted blood prime on CPB [43, 44] , with a negligible effect of varying albumin concentrations on PTA [44] .
Our next study will be to validate our model data, which will also include the measurement of the fractions of CXM.
Conclusions
In summary, we found a relevant effect of CPB on the clearance of CXM. A continuous infusion regimen using a '25 mg kg À1 bolus -25 mg kg À1 prime -5 mg kg À1 h À1 infusion' protocol improved the compliance and PTA, especially during prolonged procedures where redosing is of utmost importance. If continuous infusion is excluded, although it is our first choice, readministration of cefuroxime after CPB initiation or every 2-3 h would be an alternative which is lowrisk, low-cost and potentially highly beneficial.
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